Compare iShares MSCI Japan ETF (EWJ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Japan ETF trades at $97.8, while Zimmer Biomet Holdings Inc trades at $96.48 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares MSCI Japan ETF pays none, and iShares MSCI Japan ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| EWJ | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $107.71 |
52-Week Low | $77.93 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.68, up 1.7% on the day, with a bullish technical signal driven by moving averages. The ETF's performance is influenced by Japan's economic policies, including recent U.S.-Japan yen intervention and domestic stimulus efforts. Key support sits at $96, while resistance is at $97, with the RSI indicating potential overbought conditions.
Outlook remains tied to Japan's economic reforms and currency stability, offering exposure to Japanese equities but with risks from yen volatility and inflation. Investor sentiment is cautious amid BOJ policy uncertainty, though institutional interest persists for diversification benefits.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
